Mounjaro for PCOS: Insurance Coverage and Real Cost in 2025

What "off-label" actually means for your prescription and your wallet

Tirzepatide is approved by the FDA for two indications. Mounjaro carries approval for type 2 diabetes management, granted in May 2022. Zepbound, the same molecule, received approval in November 2023 for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related comorbidity.

PCOS is neither of those indications.

When a clinician writes "tirzepatide" on a prescription pad and codes it to a PCOS diagnosis, that is off-label prescribing. Off-label prescribing is legal and medically common. The American College of Obstetricians and Gynecologists notes that off-label medication use is sometimes the standard of care in women's health, given the historical under-representation of women in clinical trials. What off-label status does affect, directly and painfully, is insurance reimbursement.

Why insurers push back on PCOS as a diagnosis code

Insurance medical-necessity criteria are built around FDA-approved indications and established clinical guidelines. PCOS (ICD-10 code E28.2) does not appear on most insurers' preferred-drug lists or coverage criteria for tirzepatide. A plan that covers Zepbound for obesity will frequently deny the same drug when the primary diagnosis is PCOS, even if the patient has a BMI above 30, because the paperwork did not arrive framed around the obesity comorbidity.

This matters practically: the diagnosis your prescriber lists on the prior-authorization form is often the single variable that determines approval or denial.

How the dual-diagnosis pathway changes things

Many women with PCOS carry at least one additional diagnosis that is a recognized Zepbound indication, most often obesity (BMI 30+) or overweight (BMI 27+) with dyslipidemia, hypertension, or obstructive sleep apnea. Approximately 50 to 80 percent of women with PCOS are overweight or have obesity. If your prescriber submits a prior-authorization request listing obesity as the primary indication and PCOS as a secondary condition, approval rates improve substantially, though "substantially" still does not mean reliably.

What commercial insurance actually covers in 2025

Coverage for GLP-1 and GIP/GLP-1 drugs is fragmented across commercial plans, employer self-funded plans, Medicaid, and Medicare.

Commercial (employer-sponsored) insurance

A 2024 KFF analysis found that about 40 percent of large employers covered GLP-1 drugs for weight loss, up from 25 percent in 2022. The trend is moving in the right direction, but it also means roughly 60 percent of large employers do not cover weight-loss GLP-1 drugs at all. Smaller employers are less likely to cover them.

Even plans that cover Zepbound for weight loss commonly impose:

• Step therapy requiring documented failure on lifestyle modification, sometimes metformin or orlistat first
• BMI thresholds (typically 30+, or 27+ with documented comorbidity)
• Prior-authorization renewal every 6 to 12 months with weight-loss benchmarks (often 5 percent body weight at 12 weeks)
• Quantity limits aligned to the labeled dose escalation schedule

If your plan falls into the non-covering 60 percent, you are looking at full list price unless you find an alternative pathway.

Medicaid

Federal Medicaid law does not require states to cover weight-loss drugs. As of mid-2025, fewer than half of state Medicaid programs cover Zepbound or Wegovy for obesity, and coverage for Mounjaro is generally limited to members with a type 2 diabetes diagnosis. Women with PCOS who do not have a T2D or covered-obesity code face near-universal Medicaid denial.

Medicare

Medicare Part D excluded coverage of drugs "used for weight loss" under statute until the Inflation Reduction Act provisions began phasing in. As of 2025, Medicare does not yet broadly cover GLP-1s for obesity-only indications; coverage remains tied to FDA-approved cardiovascular or diabetes indications. This matters less for the core PCOS population (reproductive-age women), but it is relevant for perimenopausal women in their late 40s who are approaching Medicare age with ongoing PCOS sequelae.

Prior-authorization: the practical checklist

If your prescriber is submitting a prior authorization for tirzepatide, here is what typically strengthens the case:

• Primary diagnosis coded as obesity (E66.9) or overweight (E66.09), with BMI documented in the chart
• Secondary diagnosis listing PCOS (E28.2) and insulin resistance (E11.65 or R73.09 as appropriate)
• Documentation of prior treatment: metformin trial with dates, dietary counseling, lifestyle program
• Labs supporting metabolic dysfunction: fasting insulin, HOMA-IR, fasting glucose, lipid panel, testosterone
• Prescriber specialty noted as OB-GYN, reproductive endocrinologist, or obesity medicine

A letter of medical necessity from a specialist carries more weight than a primary-care letter in many plan review processes.

The real numbers: what you will pay without coverage

Mounjaro list price by dose

Mounjaro is dispensed in single-dose autoinjector pens. All doses carry the same list price of approximately $1,060 for a 4-week supply regardless of strength, because each carton contains four pens. The labeled starting dose for most patients is 2.5 mg weekly for four weeks, escalating to 5 mg. Doses continue to escalate at 4-week intervals to a maximum of 15 mg weekly.

Zepbound list price and cash-pay vials

Zepbound single-dose pens carry a list price similar to Mounjaro (~$1,060/month). Eli Lilly introduced Zepbound in vials specifically for cash-pay patients: 2.5 mg and 5 mg vials are available at approximately $349 and $549 per month, respectively, through LillyDirect. These lower-dose vials cover the starting and early maintenance phases, where most PCOS patients with no obesity comorbidity begin. They require self-injection using an insulin syringe and are not available through standard retail pharmacies.

Manufacturer savings programs

Eli Lilly offers a savings card for Mounjaro that can bring the monthly cost to $25 for eligible commercially insured patients who do not have government insurance (Medicare, Medicaid, TRICARE). The card is not usable if your plan does not cover Mounjaro at all, because there is no claim to attach it to. Some pharmacies can process it as a cash transaction with the card stacked on top, but eligibility rules are complex and change.

A separate Zepbound savings card program applies to that brand on similar terms.

The WomanRx Cost-Navigation Framework for PCOS patients pursuing tirzepatide follows a sequence: (1) Ask your prescriber to submit under the obesity indication if your BMI qualifies, not the PCOS code alone. (2) If denied, file an appeal with a specialist letter of medical necessity documenting PCOS-related insulin resistance and prior metformin failure. (3) If appeal fails or plan excludes weight-loss drugs categorically, pivot to Zepbound vials via LillyDirect for the starting doses. (4) Explore compounded tirzepatide from a 503A compounding pharmacy only after the branded options are exhausted, and only with a prescriber who will monitor labs. (5) Reassess insurance tier at open enrollment; employer plan formularies shift year to year.

Compounded tirzepatide: the lower-cost option with caveats

The FDA declared a tirzepatide shortage beginning in late 2023. During a shortage, 503A and 503B compounding pharmacies are permitted to produce copies. The shortage status for certain doses was removed in phases through 2024 and 2025, and the FDA confirmed in early 2025 that the shortage has been resolved for all doses, meaning 503A pharmacies are no longer permitted to compound copies of tirzepatide.

503B outsourcing facilities that received enforcement discretion during the shortage were required to wind down by specific deadlines.

This means compounded tirzepatide is in a legally complex position as of mid-2025. Some telehealth platforms still offer it; many have stopped. If you are comparing a $200/month telehealth quote for "compounded tirzepatide" against a $1,060 list price, the legal and quality questions are real. The FDA has issued warnings about unapproved compounded versions containing the wrong salt form or incorrect excipients.

The bottom line: compounded tirzepatide may still be available through some channels, but you should ask your prescriber directly whether the pharmacy they are using is a licensed 503A or 503B facility, what the current shortage status is, and whether the product has been independently tested for potency.

Sex-specific physiology: why tirzepatide is particularly relevant to PCOS

PCOS is a condition of hormonal and metabolic dysregulation. The three diagnostic criteria under Rotterdam require two of: oligo- or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. Between 50 and 70 percent of women with PCOS have insulin resistance, even those who are lean, making insulin sensitization central to PCOS management.

Tirzepatide works differently from older GLP-1 agonists. It is a dual GIP/GLP-1 receptor agonist. By activating both pathways, it produces greater reductions in body weight and fasting insulin than GLP-1 mono-agonists in head-to-head comparisons. The SURMOUNT-1 trial in adults with obesity (but not diabetes) showed mean body weight reductions of 15.0 percent (10 mg) and 20.9 percent (15 mg) at 72 weeks. These are not PCOS-specific numbers, but weight reduction of that magnitude in women with PCOS is associated with meaningful restoration of ovulatory cycles and reduction in free androgen index.

How the menstrual cycle and hormonal status interact

Women with PCOS commonly have elevated luteinizing hormone (LH) to follicle-stimulating hormone (FSH) ratios, elevated free testosterone, and suppressed sex-hormone binding globulin (SHBG). Weight loss, by reducing insulin and thereby reducing ovarian androgen production, raises SHBG and lowers free testosterone. The result is often cycle regularization. A 2023 systematic review in Fertility and Sterility found that GLP-1 receptor agonist use in women with PCOS was associated with improved menstrual regularity and reduced androgen levels, though the authors noted that most trials used liraglutide or semaglutide, not tirzepatide specifically.

There is currently no completed randomized controlled trial of tirzepatide specifically in women with PCOS. The evidence base is extrapolated from the SURPASS and SURMOUNT programs, from smaller semaglutide PCOS trials, and from mechanistic reasoning about insulin sensitization. Transparency about this gap is part of how WomanRx approaches evidence: what we know from large trials, what is extrapolated, and what has not yet been studied in your specific population.

Across reproductive life stages

Reproductive years (18 to 40). This is the primary PCOS population seeking tirzepatide. The goals are typically cycle regulation, weight reduction, acne and hirsutism improvement, and sometimes fertility restoration.

Trying to conceive. Tirzepatide must be stopped before attempting pregnancy (see the pregnancy section below). Ovulation induction agents (letrozole, clomiphene) remain first-line for PCOS-related infertility per ASRM guidelines. Tirzepatide may be used in the interval between cycles or before initiating fertility treatment to reduce BMI and improve insulin sensitivity, then discontinued.

Perimenopause. Women entering perimenopause with longstanding PCOS face compounding metabolic risk: declining estrogen, pre-existing insulin resistance, and often years of irregular cycles. Tirzepatide's metabolic effects are relevant here, but the evidence in this specific subgroup is entirely absent from published trials. Extrapolation from obesity trials is the basis of any prescribing in this age group.

Pregnancy, lactation, and contraception: required reading

Pregnancy: Tirzepatide is classified as a pregnancy Category X equivalent under current FDA labeling, meaning it should not be used during pregnancy. Animal studies showed fetal harm at doses below human therapeutic exposure. No adequate human pregnancy data exist. The FDA prescribing information for both Mounjaro and Zepbound states that tirzepatide should be discontinued at least two months before a planned pregnancy. This two-month washout period accounts for the drug's half-life of approximately five days and the time needed for plasma levels to fall below detectable thresholds.

Women with PCOS who are using tirzepatide to improve fertility should plan their contraception and washout window explicitly with their prescriber before any fertility treatment cycle begins.

Lactation: There are no human lactation studies for tirzepatide. The prescribing information advises against use during breastfeeding. The molecular weight of tirzepatide is high enough that transfer into breast milk is expected to be low, but "expected to be low" is not the same as studied and confirmed safe. Given the availability of alternative PCOS treatments, breastfeeding women should discuss the risk-benefit ratio with their clinician rather than assuming safety.

Contraception: Because tirzepatide may reduce the efficacy of oral contraceptives by altering gastric emptying for the first four weeks after each dose escalation, Eli Lilly's prescribing information recommends adding a barrier method or switching to non-oral contraception during dose escalation periods. Many women with PCOS use combined oral contraceptives to manage androgen symptoms. Discuss timing of dose escalations with your prescriber if you are on the pill.

Who this medication is right for, and who it is not

Likely a reasonable fit

• Women with PCOS who have BMI 27+ with documented insulin resistance, dyslipidemia, or hypertension, and who have tried metformin (or have a documented intolerance to it)
• Women with PCOS who have BMI 30+ and whose primary weight-loss comorbidity can be coded for insurance purposes
• Women planning a future pregnancy who want to reduce BMI and improve ovulatory function before initiating fertility treatment, with a clear plan to stop tirzepatide at least two months before conception
• Women with PCOS in whom metformin alone has not achieved adequate glycemic or weight targets

Probably not the right fit right now

• Women currently trying to conceive or pregnant
• Women who are breastfeeding (insufficient safety data)
• Women whose only PCOS phenotype is hyperandrogenism without metabolic features, where the risk-benefit is less clear
• Women with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome (contraindication per labeling)
• Women who cannot afford any out-of-pocket cost and whose insurance categorically excludes weight-loss drugs, unless they are prepared to pursue compounded options with eyes open to the current regulatory uncertainty

Practical steps to take at your next appointment

First, ask your prescriber to pull your most recent HOMA-IR, fasting insulin, testosterone (total and free), SHBG, and lipid panel if these have not been checked in the past six months. These labs build the clinical picture that supports a prior-authorization letter and also give you a baseline to assess whether the medication is working.

Second, find out exactly what your plan covers before the prescription is written. A benefits call with your insurer, asking specifically whether Zepbound is covered for obesity and what the step-therapy requirements are, takes about 20 minutes and can save you from a surprise $1,060 bill.

Third, if your BMI is 27 or above and you have any of the recognized comorbidities (dyslipidemia, hypertension, sleep apnea), ask your prescriber to consider coding the primary indication as obesity with comorbidity, not PCOS alone. This is not dishonest; it is accurate framing of your actual clinical picture.

Fourth, if cost is a barrier after all of that, ask your prescriber specifically about the Zepbound vial program through LillyDirect, which at $349/month for the 2.5 mg starting dose represents the most cost-accessible branded option currently available without insurance.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy supports use of GLP-1 and dual agonist therapies in women with metabolic complications of PCOS, while acknowledging the need for PCOS-specific trial data. That data gap means you and your prescriber are making a decision based on strong mechanistic reasoning and large obesity-trial evidence, but not on a dedicated PCOS trial. Knowing that distinction helps you set realistic expectations and ask the right follow-up questions over the coming months of treatment.